Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung

Abstract

Background: There are few reports about the factor influencing the prognosis of high-grade neuroendocrine carcinoma. In this study, we evaluated surgical outcome of clinical stage I high-grade neuroendocrine carcinoma. Methods: Patients who underwent curative surgery for high-grade neuroendocrine tumors of the lung in clinical stage I were included in this study. We retrospectively analyzed 27 consecutive patients. The aim of this study was to clarify the clinical course of the disease after surgery and what factors influence the prognosis. Results: Twenty-two patients have small cell carcinoma, and 5 patients have large cell neuroendocrine carcinoma. Patients who could undergo surgery within 60days after the first visit (p<0.01) and undergo lobectomy (p<0.01) and whose pro-gastrin-releasing peptide ≦72pg/ml (p=0.04) performed good prognosis after surgery. In multivariate analysis, surgery within 60days and operative procedure were independent factors associated with OS. Conclusion: Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung should be performed as early as possible, and better outcome can be obtained with lobectomy than partial resection.